Spotting the Cure: How Hybrid Drugs Could Change the View for Dry AMD - Neil Josen Delos Reyes

This research develops a hybrid drug for dry age-related macular degeneration, combining anti-inflammatory and antioxidant mechanisms. By targeting both inflammation and oxidative stress, it aims to slow disease progression more effectively than existing treatments. Laboratory models test whether the combined therapy outperforms individual or co-administered components in preserving retinal function.